- Home
- OFS vs LPTX Comparison
OFS vs LPTX Comparison
Compare OFS & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OFS
- LPTX
- Stock Information
- Founded
- OFS 2001
- LPTX 2011
- Country
- OFS United States
- LPTX United States
- Employees
- OFS N/A
- LPTX N/A
- Industry
- OFS Finance/Investors Services
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OFS Finance
- LPTX Health Care
- Exchange
- OFS Nasdaq
- LPTX Nasdaq
- Market Cap
- OFS 108.5M
- LPTX 119.6M
- IPO Year
- OFS 2012
- LPTX N/A
- Fundamental
- Price
- OFS $8.10
- LPTX $0.53
- Analyst Decision
- OFS
- LPTX Buy
- Analyst Count
- OFS 0
- LPTX 3
- Target Price
- OFS N/A
- LPTX $8.50
- AVG Volume (30 Days)
- OFS 31.1K
- LPTX 1.4M
- Earning Date
- OFS 03-03-2025
- LPTX 03-17-2025
- Dividend Yield
- OFS 16.80%
- LPTX N/A
- EPS Growth
- OFS N/A
- LPTX N/A
- EPS
- OFS N/A
- LPTX N/A
- Revenue
- OFS $49,799,000.00
- LPTX N/A
- Revenue This Year
- OFS N/A
- LPTX N/A
- Revenue Next Year
- OFS N/A
- LPTX N/A
- P/E Ratio
- OFS N/A
- LPTX N/A
- Revenue Growth
- OFS N/A
- LPTX N/A
- 52 Week Low
- OFS $7.75
- LPTX $0.50
- 52 Week High
- OFS $11.94
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- OFS 50.99
- LPTX 17.79
- Support Level
- OFS $7.92
- LPTX $2.03
- Resistance Level
- OFS $8.17
- LPTX $2.39
- Average True Range (ATR)
- OFS 0.10
- LPTX 0.24
- MACD
- OFS 0.01
- LPTX -0.24
- Stochastic Oscillator
- OFS 84.00
- LPTX 0.70
About OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .